Hoang Trang T T, Ichinose Kunihiro, Morimoto Shimpei, Furukawa Kaori, Le Ly H T, Kawakami Atsushi
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Clin Immunol. 2022 Apr;237:108980. doi: 10.1016/j.clim.2022.108980. Epub 2022 Mar 13.
Neuropsychiatric systemic lupus erythematosus (NPSLE) varies in presentation and is one of the leading causes of morbidity and mortality among patients with SLE. This study determined the most critical serum biomarkers for the development of NPSLE as they may have clinical utility prior to the onset of neuropsychiatric symptoms. We retrospectively analyzed 35 NPSLE patients, 34 SLE patients, 20 viral meningitis (VM) patients, and 16 relapsing-remitting multiple sclerosis (MS) patients. We measured anti-suprabasin antibodies concentrations in serum by using Luciferase immunoprecipitation system (LIPS) assay. The serum concentrations of cytokines/chemokines were measured by using multiplex bead-based assay. We found serum FGF-2 level was significantly higher in the NPSLE group compared to the SLE group and the healthy control group. The anti-suprabasin antibody relative concentration (SRC) has high positive predictive values for the development of NPSLE. The most essential biomarkers are VEGF, anti-suprabasin antibodies, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNF-α, MIP-1α.
神经精神性系统性红斑狼疮(NPSLE)临床表现各异,是系统性红斑狼疮(SLE)患者发病和死亡的主要原因之一。本研究确定了NPSLE发生的最关键血清生物标志物,因为它们可能在神经精神症状出现之前具有临床应用价值。我们回顾性分析了35例NPSLE患者、34例SLE患者、20例病毒性脑膜炎(VM)患者和16例复发缓解型多发性硬化症(MS)患者。我们使用荧光素酶免疫沉淀系统(LIPS)测定法测量血清中抗上层基底膜抗体浓度。使用基于多重微珠的测定法测量细胞因子/趋化因子的血清浓度。我们发现,与SLE组和健康对照组相比,NPSLE组的血清FGF-2水平显著更高。抗上层基底膜抗体相对浓度(SRC)对NPSLE的发生具有较高的阳性预测价值。最关键的生物标志物是血管内皮生长因子(VEGF)、抗上层基底膜抗体、可溶性CD40配体(sCD40L)、白细胞介素-10(IL-10)、生长调节致癌基因α(GRO)、巨噬细胞来源的趋化因子(MDC)、白细胞介素-8(IL-8)、白细胞介素-9(IL-9)、肿瘤坏死因子-α(TNF-α)、巨噬细胞炎性蛋白-1α(MIP-1α)。